These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 2652614)

  • 1. Aggressive needle biopsy protocol prevents loss of renal allografts to undetected rejection during early posttransplant dysfunction.
    Thistlethwaite JR; Woodle ES; Mayes JT; Stuart JK; Heffron TG; Spargo BH; Stuart FP
    Transplant Proc; 1989 Feb; 21(1 Pt 2):1890-2. PubMed ID: 2652614
    [No Abstract]   [Full Text] [Related]  

  • 2. Triple immunosuppressive therapy in immunologic high-risk renal allograft recipients.
    Cole E; Robinson C; Bear R
    Transplant Proc; 1989 Feb; 21(1 Pt 2):2026-7. PubMed ID: 2652662
    [No Abstract]   [Full Text] [Related]  

  • 3. Conversion to triple therapy in renal allograft patients with renal dysfunction and chronic interstitial lesions or vascular lesions on renal biopsy.
    Leaker B; Neild GH; Rudge C; Mansell M; Thompson FD
    Transplant Proc; 1989 Feb; 21(1 Pt 2):1548-9. PubMed ID: 2652501
    [No Abstract]   [Full Text] [Related]  

  • 4. Effect of duration of MALG therapy in a quadruple immunosuppressive protocol.
    Stratta RJ; D'Alessandro AM; Armbrust MJ; Pirsch JD; Sollinger HW; Kalayoglu M; Belzer FO
    Transplant Proc; 1989 Feb; 21(1 Pt 2):1726-8. PubMed ID: 2652564
    [No Abstract]   [Full Text] [Related]  

  • 5. Quadruple drug therapy prevents graft loss from acute rejection without increasing mortality.
    Light JA; Aquino A; Ali A; Rodriguez R; Ali S
    Transplant Proc; 1987 Feb; 19(1 Pt 3):1927-30. PubMed ID: 3547897
    [No Abstract]   [Full Text] [Related]  

  • 6. Quadruple therapy for cadaver renal transplantation.
    Deierhoi MH; Sollinger HW; Kalayoglu M; Belzer FO
    Transplant Proc; 1987 Feb; 19(1 Pt 3):1917-9. PubMed ID: 3274452
    [No Abstract]   [Full Text] [Related]  

  • 7. Effect of discontinuing or restricting cyclosporine on late renal allograft rejection and function.
    Woodle ES; Heffron TG; Stuart JK; Thistlethwaite JR; Stuart FP
    Transplant Proc; 1989 Feb; 21(1 Pt 2):1641-2. PubMed ID: 2652536
    [No Abstract]   [Full Text] [Related]  

  • 8. Pediatric renal transplantation results are improved with triple drug therapy with cyclosporine, azathioprine, and prednisone.
    MacDonell RC; Johnson K; Richie R; Nylander W; McMahon Y; Niblack G; Green W; Morrissey J; Ynares C
    Transplant Proc; 1989 Feb; 21(1 Pt 2):1701-4. PubMed ID: 2652557
    [No Abstract]   [Full Text] [Related]  

  • 9. Control of rejection of transplanted organs.
    Keown PA; Stiller CR
    Adv Intern Med; 1986; 31():17-46. PubMed ID: 3511616
    [No Abstract]   [Full Text] [Related]  

  • 10. Definition, diagnosis, and management of rejection in the second to sixth months posttransplant--an overview.
    Matas AJ; Tellis VA; Quinn T; Soberman R; Veith FJ
    Transplant Proc; 1986 Apr; 18(2 Suppl 1):141-50. PubMed ID: 3515682
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An immunosuppressive protocol compatible with the United States kidney transplant diagnosis related grouping.
    Stuart FP; Stuart JK; Thistlethwaite JR; Gaber AO; Mayes J
    Transplant Proc; 1987 Feb; 19(1 Pt 3):1959-60. PubMed ID: 3152656
    [No Abstract]   [Full Text] [Related]  

  • 12. Early graft function in primary and regraft recipients of paired cadaveric kidneys.
    Jaklitsch MT; Deierhoi MH; Hudson S; Barber WH; Barger BO; Phillips MG; Diethelm AG
    Transplant Proc; 1989 Feb; 21(1 Pt 2):1274-5. PubMed ID: 2652421
    [No Abstract]   [Full Text] [Related]  

  • 13. The role of antilymphocyte globulin in cadaver renal transplantation.
    Novick AC
    Transplant Proc; 1986 Jun; 18(3 Suppl 2):22-7. PubMed ID: 3521000
    [No Abstract]   [Full Text] [Related]  

  • 14. Dallas experience with cyclosporine A (CsA) one to six months posttransplant.
    Hull AR; Atkins CR; Brinker KR; Dawidson I; Dickerman RM; Emerson W; Helderman JH; Levitz B; Long DL; Nesser D
    Transplant Proc; 1986 Apr; 18(2 Suppl 1):128-31. PubMed ID: 3515679
    [No Abstract]   [Full Text] [Related]  

  • 15. Cox regression analysis of outcome risk factors in 519 renal allograft recipients.
    Canafax DM; Savik SK; Draxler CA; Le CT; Ascher NL; Payne WD; Sutherland DE; Migliori RJ; Simmons RL; Najarian JS
    Transplant Proc; 1987 Feb; 19(1 Pt 3):1947-8. PubMed ID: 3274455
    [No Abstract]   [Full Text] [Related]  

  • 16. Cyclosporine-steroids versus conventional therapy in cadaver kidney transplantation: analysis of a randomized trial at two years.
    Gianello P; Squifflet JP; Pirson Y; Stoffel M; Dereme T; Alexandre GP
    Transplant Proc; 1987 Feb; 19(1 Pt 3):1867-72. PubMed ID: 3547891
    [No Abstract]   [Full Text] [Related]  

  • 17. Use of OKT3 in kidney, pancreas, and liver transplantation.
    D'Alessandro AM; Pirsch JD; Melzer JS; Sollinger HW; Kalayoglu M; Reed A; Knechtle SJ; Belzer FO
    Transplant Proc; 1990 Aug; 22(4):1748-9. PubMed ID: 2117796
    [No Abstract]   [Full Text] [Related]  

  • 18. Role of protocol biopsies in the treatment of refractory renal allograft rejection with FK 506.
    Woodle ES; Thistlethwaite JR; Haas M; Josephson MA; Newell KA; Bruce DS; Millis JM; Piper JB; Charette JI
    Transplant Proc; 1996 Apr; 28(2):998-9. PubMed ID: 8623495
    [No Abstract]   [Full Text] [Related]  

  • 19. Primary dysfunction of renal allografts as a risk factor.
    Margreiter R; Bösmüller C; Spielberger M; Königsrainer A; Dünser M
    Transplant Proc; 1990 Aug; 22(4):1373-4. PubMed ID: 2389333
    [No Abstract]   [Full Text] [Related]  

  • 20. Quadruple drug induction treatment in patients with ATN-kidneys: expensive but effective.
    Schilling M; Schleibner S; Abendroth D; Illner WD; Schneeberger H; Land W
    Transplant Proc; 1990 Oct; 22(5):2283. PubMed ID: 2219369
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.